Related Experiment Video
Updated: Aug 8, 2026

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
Published on: May 9, 2018
[The efficacy of alfuzosin (dalfaz) in patients with benign prostatic hyperplasia]
Abstract:
A daily dose of alfusosine (an uroselective blocker alpha-l-adrenoreceptors produced as dalfas by Synthelabo Group, France) was given for 12 weeks to 124 patients with benign prostatic hyperplasia. The patients were examined before the treatment and on the treatment week 4, 8 and 12. The response (improved quality of life, higher rate of urine flow, smaller amount of residual urine in the bladder) was achieved in 120 (96%) patients. Alfusosine effect was more pronounced in patients with severe defects of urination. The drug was well tolerated, side effects observed in 7(5.6%) patients were mild and did not require treatment discontinuation. Alfusosine is indicated in benign prostatic hyperplasia with moderate infravesical obstruction, significantly disturbed urination caused by hypertonicity of bladder cervix smooth muscles, posterior urethra and prostate.
Related Concept Videos
Dose-Response Relationship: Potency and Efficacy
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Urodynamic Studies: Uroflowmetry

